IL1RL2 and psoriasis: Here, we investigated the consequences of an anti-IL36R treatment in two mouse models of IL-17A-driven psoriasis: in IMQ-treated mice and in mice that overexpress IL-17A in the epidermis, thus developing IL-17A-depending psoriatic lesions.